Skip to content
A5218Assembly2021-2022 SessionSame asS2006

Drug Rebates Go to Patients

Official title

“Requires certain insurance carriers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale”

Sponsor Latrice WalkerAD-55+1 co-sponsorAffects Finance
Status
In Assembly Committee
Insurance
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires health insurers to certify that most prescription drug rebates are provided to patients at the point of sale.

Why it matters

  1. Increases transparency and accountability. by requiring insurers to certify annually that over half of all prescription drug rebates are passed directly to patients at the point of sale, rather than being retained by insurers or pharmacy benefit managers.

  2. May reduce out-of-pocket costs for consumers. at the pharmacy counter, as patients could benefit from immediate price reductions on prescription drugs rather than waiting for indirect savings or lower premiums over time.

  3. Defines "rebate" broadly. to include not just direct manufacturer rebates but also price protection rebates, performance-based rebates, and certain administrative fees, potentially capturing a wide scope of savings for patient benefit.

  4. Protects proprietary business information. by ensuring that detailed rebate data at the product, manufacturer, or pharmacy level remains confidential, which could address industry concerns about trade secrets while still providing oversight.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients enrolled in covered health plans

    The bill would require insurers to certify that more than half of prescription drug rebates were made available to enrollees at the point of sale.

  • Individual, small-group, and group and blanket health insurers

    They would have to submit annual certifications covering the prior benefit year and protect product-, manufacturer- and pharmacy-specific rebate amounts from disclosure.

  • Third-party prescription benefit administrators and vendors

    Rebates received by administrators on insurers’ behalf would count toward the certification, and contractors with access to rebate information would be subject to confidentiality protections.

  • State insurance regulators

    The department would receive insurers’ annual certifications that they met the point-of-sale rebate requirement.

Headline styles

Drug Rebates Go to Patients

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Latrice Walker

Assembly Member · Assembly District 55

Chair, Election Law

History

  1. Referred to insurance
  2. Print number 5218a
  3. Amend and recommit to insurance
  4. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S2006Senate

Rebates Go To Patients

In Senate Committee · Insurance · Sponsor Robert Jackson

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

5218--A

2021-2022 Regular Sessions

IN ASSEMBLY

February 12, 2021

Introduced by M. of A. WALKER -- read once and referred to the Committee on Insurance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the insurance law, in relation to requiring individual and small group insurance carriers and group and blanket accident and health carriers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 1 of subsection (e) of section 3231 of the insurance law is amended by adding a new subparagraph (C) to read as follows:

(C) an insurer shall annually certify to the department that, during the prior benefit year, the insurer made available to enrollees at the point of sale at least a majority (i.e., greater than fifty percent) of the rebates received by such insurer or any third party administering prescription drug benefits on behalf of such insurer.

(i) For purposes of this paragraph, "rebate" means:

(1) negotiated price concessions including but not limited to base rebates and reasonable estimates of any price protection rebates and performance-based rebates that may accrue directly or indirectly to the issuer during the coverage year from a manufacturer, dispensing pharmacy, or other party to the transaction, and

(2) reasonable estimates of any fees and other administrative costs that are passed through to the issuer and serve to reduce the issuer's prescription drug liabilities for the coverage year.

(ii) In providing the certification required under this subparagraph, an issuer shall not publish or otherwise reveal information regarding the actual amount of rebates the issuer received on a product-, manufacturer- or pharmacy-specific basis. Such information is protected as a trade secret, is not a public record as defined in the public officers law and shall not be disclosed directly or indirectly. An insurer shall

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02313-03-1

A. 5218--A 2

impose the confidentiality protections of this subparagraph on any third parties or vendors with which it contracts that may receive or have access to rebate information.

§ 2. Subsection (b) of section 3221 of the insurance law is amended to read as follows:

(b) (1) No such policy shall be delivered or issued for delivery in this state unless a schedule of the premium rates pertaining to such form shall have been filed with the superintendent.

(2) An insurer shall annually certify to the department that, during the prior benefit year, the insurer made available to enrollees at the point of sale at least a majority (i.e., greater than fifty percent) of the rebates received by such insurer or any third party administering prescription drug benefits on behalf of such insurer.

(A) For purposes of this paragraph, "rebate" means:

(i) negotiated price concessions including but not limited to base rebates and reasonable estimates of any price protection rebates and performance-based rebates that may accrue directly or indirectly to the issuer during the coverage year from a manufacturer, dispensing pharmacy, or other party to the transaction, and

(ii) reasonable estimates of any fees and other administrative costs that are passed through to the issuer and serve to reduce the issuer's prescription drug liabilities for the coverage year.

(B) In providing the certification required under this subsection, an issuer shall not publish or otherwise reveal information regarding the actual amount of rebates the issuer received on a product-, manufacturer- or pharmacy-specific basis. Such information is protected as a trade secret, is not a public record as defined in the public officers law and shall not be disclosed directly or indirectly. An insurer shall impose the confidentiality protections of this subsection on any third parties or vendors with which it contracts that may receive or have access to rebate information.

§ 3. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.